血管内皮抑素临床研究进展

抑制血管生成是治疗肿瘤的一种新策略,血管内皮抑素(ES)作为一种内源性血管生成抑制剂,在肿瘤治疗中有广阔的应用前景。其作用特点表现为特异性、广泛性和组织差异性。临床试验结果显示不易产生耐药性和无明显毒副作用的药理特征。针对单独给药疗效的不尽如意,与传统治疗方案联合协同增效达到治疗肿瘤的目的为其发展趋势之一,同时进一步改进药物形式降低成本和提高药物活性、稳定性及靶向性是另一研究方向。

Progress in clinical study of endostatin

Antiangiogenic therapy is becoming a new therapeutic modality of anti-cancer therapy.Endostatin,as an endogenous angiogenesis inhibitor,will have an extensive application in cancer treat- ment.Antiangiogenic effects of endostatin are characterized as specific,broad and tumour type-dependently dif- ferential.Clinical trials indicate that therapy with endostatin has a lower risk of drug resistance and relatively less toxicity.Because the results of treatment in humans are less exciting than what might be expected from the preclinical data,synergistic anti-tumor effects of endostatin plus conventional therapy should be one trend for en- dostatin therapy.Furthermore,it's important to improve the drug form furtherly for reducing the cost and in- creasing the activity,stability and targeted ability of endostatin.